Fox Chase Cancer Center
SABCS Update on HER2+ EBC: Extended Adjuvant Neratinib, T-DM1 vs. TH, T-DM1 PFS vs. Trastuzumab, Optimal Duration of Trastuzumab, DFS With Adjuvant Pertuzumab in LN+ Disease
By
Fox Chase Cancer Center
FEATURING
Lori Goldstein
By
Fox Chase Cancer Center
FEATURING
Lori Goldstein
Comments 0
Login to view comments.
Click here to Login
